# A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

> **NCT00301535** · PHASE2 · UNKNOWN · sponsor: **Biopure Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** HBOC-201 (hemoglobin glutamer-250 bovine)

## Key facts

- **NCT ID:** NCT00301535
- **Lead sponsor:** Biopure Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2008-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301535, "A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00301535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*